123.06 USD
-1.14 (-0.92%)
123.06 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to TMDX. TMDX was compared to 186 industry peers in the Health Care Equipment & Supplies industry. While TMDX has a great health rating, its profitability is only average at the moment. TMDX is not priced too expensively while it is growing strongly. Keep and eye on this one! With these ratings, TMDX could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
TMDX had positive earnings in the past year.
In the past year TMDX had a positive cash flow from operations.
TMDX had negative earnings in 4 of the past 5 years.
In the past 5 years TMDX reported 4 times negative operating cash flow.
1.2 Ratios
TMDX's Return On Assets of 9.70% is amongst the best of the industry. TMDX outperforms 93.55% of its industry peers.
TMDX has a better Return On Equity (25.84%) than 96.77% of its industry peers.
TMDX's Return On Invested Capital of 8.75% is amongst the best of the industry. TMDX outperforms 88.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.7% | ||
| ROE | 25.84% | ||
| ROIC | 8.75% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TMDX has a Profit Margin of 16.20%. This is amongst the best in the industry. TMDX outperforms 93.01% of its industry peers.
TMDX's Operating Margin of 16.94% is amongst the best of the industry. TMDX outperforms 87.63% of its industry peers.
Looking at the Gross Margin, with a value of 60.28%, TMDX is in the better half of the industry, outperforming 61.29% of the companies in the same industry.
TMDX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.94% | ||
| PM (TTM) | 16.2% | ||
| GM | 60.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
2. Health
2.1 Basic Checks
TMDX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, TMDX has more shares outstanding
TMDX has more shares outstanding than it did 5 years ago.
TMDX has a better debt/assets ratio than last year.
2.2 Solvency
TMDX has an Altman-Z score of 5.35. This indicates that TMDX is financially healthy and has little risk of bankruptcy at the moment.
TMDX has a better Altman-Z score (5.35) than 79.03% of its industry peers.
The Debt to FCF ratio of TMDX is 4.24, which is a neutral value as it means it would take TMDX, 4.24 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.24, TMDX belongs to the top of the industry, outperforming 80.11% of the companies in the same industry.
TMDX has a Debt/Equity ratio of 1.43. This is a high value indicating a heavy dependency on external financing.
TMDX's Debt to Equity ratio of 1.43 is on the low side compared to the rest of the industry. TMDX is outperformed by 79.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.24 | ||
| Altman-Z | 5.35 |
ROIC/WACC1.09
WACC8.02%
2.3 Liquidity
A Current Ratio of 7.69 indicates that TMDX has no problem at all paying its short term obligations.
TMDX has a better Current ratio (7.69) than 88.71% of its industry peers.
TMDX has a Quick Ratio of 7.13. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 7.13, TMDX belongs to the best of the industry, outperforming 89.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.69 | ||
| Quick Ratio | 7.13 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 162.77% over the past year.
TMDX shows a strong growth in Revenue. In the last year, the Revenue has grown by 41.20%.
Measured over the past years, TMDX shows a very strong growth in Revenue. The Revenue has been growing by 79.64% on average per year.
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
3.2 Future
Based on estimates for the next years, TMDX will show a very strong growth in Earnings Per Share. The EPS will grow by 44.52% on average per year.
The Revenue is expected to grow by 21.23% on average over the next years. This is a very strong growth
EPS Next Y163.67%
EPS Next 2Y71.04%
EPS Next 3Y53.35%
EPS Next 5Y44.52%
Revenue Next Year39.67%
Revenue Next 2Y29.73%
Revenue Next 3Y25.56%
Revenue Next 5Y21.23%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 49.82 indicates a quite expensive valuation of TMDX.
Based on the Price/Earnings ratio, TMDX is valued a bit cheaper than the industry average as 68.82% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.84, TMDX is valued quite expensively.
A Price/Forward Earnings ratio of 41.65 indicates a quite expensive valuation of TMDX.
Based on the Price/Forward Earnings ratio, TMDX is valued a bit cheaper than the industry average as 70.43% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.40, TMDX is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.82 | ||
| Fwd PE | 41.65 |
4.2 Price Multiples
69.89% of the companies in the same industry are more expensive than TMDX, based on the Enterprise Value to EBITDA ratio.
77.42% of the companies in the same industry are more expensive than TMDX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 34.87 | ||
| EV/EBITDA | 35.26 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TMDX's earnings are expected to grow with 53.35% in the coming years.
PEG (NY)0.3
PEG (5Y)N/A
EPS Next 2Y71.04%
EPS Next 3Y53.35%
5. Dividend
5.1 Amount
No dividends for TMDX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
123.06
-1.14 (-0.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners111.26%
Inst Owner Change1.46%
Ins Owners2.95%
Ins Owner Change-0.16%
Market Cap4.20B
Revenue(TTM)566.35M
Net Income(TTM)91.77M
Analysts83
Price Target148.84 (20.95%)
Short Float %23.26%
Short Ratio8.23
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.22%
Min EPS beat(2)84.39%
Max EPS beat(2)100.04%
EPS beat(4)4
Avg EPS beat(4)92.06%
Min EPS beat(4)16.42%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)202.42%
EPS beat(12)10
Avg EPS beat(12)118.6%
EPS beat(16)12
Avg EPS beat(16)90.24%
Revenue beat(2)1
Avg Revenue beat(2)0.71%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)4.34%
Revenue beat(4)3
Avg Revenue beat(4)5.83%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)7.35%
Revenue beat(12)10
Avg Revenue beat(12)12.14%
Revenue beat(16)14
Avg Revenue beat(16)18.13%
PT rev (1m)1.74%
PT rev (3m)-0.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.51%
EPS NY rev (1m)0.62%
EPS NY rev (3m)10.25%
Revenue NQ rev (1m)-0.12%
Revenue NQ rev (3m)0.3%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)-0.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.82 | ||
| Fwd PE | 41.65 | ||
| P/S | 7.42 | ||
| P/FCF | 34.87 | ||
| P/OCF | 23.58 | ||
| P/B | 11.84 | ||
| P/tB | 12.31 | ||
| EV/EBITDA | 35.26 |
EPS(TTM)2.47
EY2.01%
EPS(NY)2.95
Fwd EY2.4%
FCF(TTM)3.53
FCFY2.87%
OCF(TTM)5.22
OCFY4.24%
SpS16.57
BVpS10.4
TBVpS10
PEG (NY)0.3
PEG (5Y)N/A
Graham Number24.04
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.7% | ||
| ROE | 25.84% | ||
| ROCE | 11.08% | ||
| ROIC | 8.75% | ||
| ROICexc | 18.94% | ||
| ROICexgc | 19.61% | ||
| OM | 16.94% | ||
| PM (TTM) | 16.2% | ||
| GM | 60.28% | ||
| FCFM | 21.29% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score7
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.24 | ||
| Debt/EBITDA | 4.16 | ||
| Cap/Depr | 224.51% | ||
| Cap/Sales | 10.19% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 146.57% | ||
| Profit Quality | 131.41% | ||
| Current Ratio | 7.69 | ||
| Quick Ratio | 7.13 | ||
| Altman-Z | 5.35 |
F-Score7
WACC8.02%
ROIC/WACC1.09
Cap/Depr(3y)951.97%
Cap/Depr(5y)615.69%
Cap/Sales(3y)34.99%
Cap/Sales(5y)23.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
EPS Next Y163.67%
EPS Next 2Y71.04%
EPS Next 3Y53.35%
EPS Next 5Y44.52%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
Revenue Next Year39.67%
Revenue Next 2Y29.73%
Revenue Next 3Y25.56%
Revenue Next 5Y21.23%
EBIT growth 1Y205.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year317.92%
EBIT Next 3Y87.46%
EBIT Next 5Y68.49%
FCF growth 1Y187.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y802.91%
OCF growth 3YN/A
OCF growth 5YN/A
TRANSMEDICS GROUP INC / TMDX FAQ
Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to TMDX.
What is the valuation status for TMDX stock?
ChartMill assigns a valuation rating of 5 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.
How profitable is TRANSMEDICS GROUP INC (TMDX) stock?
TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for TMDX stock?
The Price/Earnings (PE) ratio for TRANSMEDICS GROUP INC (TMDX) is 49.82 and the Price/Book (PB) ratio is 11.84.
What is the financial health of TRANSMEDICS GROUP INC (TMDX) stock?
The financial health rating of TRANSMEDICS GROUP INC (TMDX) is 7 / 10.